Cibiem, a New York City-based medical device startup, has raised $10m in Series A financing.
Backers include SV Life Sciences and Third Rock Ventures.
Co-founded by CTO Mark Gelfand and President Howard R. Levin, M.D., Cibiem leverages its proprietary catheter-based approach focused on Carotid Body Modulation™ (CBM) for the treatment of sympathetic nervous system-mediated diseases such as hypertension, heart failure, diabetes and renal failure.
The company, which is launching out of medical device incubator Coridea, intends to use the funds to develop its device in first-in-man clinical trials.
In conjunction with the close of the deal, Jonathan Wyler, principal at SV Life Sciences, and Neil Exter, partner at Third Rock Ventures, will join Cibiem’s board of directors.
FinSMEs
17/10/2012